Shares of TherapeuticsMD Inc (NASDAQ:TXMD) have received a consensus recommendation of “Hold” from the ten brokerages that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $9.86.
Several brokerages recently commented on TXMD. Noble Financial reissued an “outperform” rating and set a $13.00 price target on shares of TherapeuticsMD in a research report on Tuesday, April 30th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $130.00 price objective (up from $116.00) on shares of Zoetis in a research report on Wednesday, June 12th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $75.00 price objective on shares of Bayerische Motoren Werke in a research report on Tuesday, May 7th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Intel in a research report on Tuesday, June 11th. Finally, BidaskClub raised Winmark from a “sell” rating to a “hold” rating in a research report on Tuesday, May 14th.
NASDAQ TXMD traded down $0.05 during trading hours on Friday, hitting $2.50. 1,379,806 shares of the company traded hands, compared to its average volume of 2,950,890. The stock has a 50-day simple moving average of $2.78. TherapeuticsMD has a twelve month low of $2.21 and a twelve month high of $6.94. The company has a quick ratio of 3.28, a current ratio of 3.39 and a debt-to-equity ratio of 1.26. The stock has a market cap of $615.12 million, a PE ratio of -4.24 and a beta of 1.88.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Metropolitan Life Insurance Co NY increased its stake in shares of TherapeuticsMD by 8.2% during the first quarter. Metropolitan Life Insurance Co NY now owns 60,906 shares of the company’s stock worth $296,000 after purchasing an additional 4,627 shares during the period. Beaumont Financial Partners LLC increased its stake in shares of TherapeuticsMD by 19.5% during the first quarter. Beaumont Financial Partners LLC now owns 35,000 shares of the company’s stock worth $170,000 after purchasing an additional 5,700 shares during the period. Greenwood Capital Associates LLC increased its stake in shares of TherapeuticsMD by 2.2% during the first quarter. Greenwood Capital Associates LLC now owns 278,858 shares of the company’s stock worth $1,358,000 after purchasing an additional 5,947 shares during the period. New York State Common Retirement Fund increased its stake in shares of TherapeuticsMD by 4.1% during the fourth quarter. New York State Common Retirement Fund now owns 179,100 shares of the company’s stock worth $682,000 after purchasing an additional 7,000 shares during the period. Finally, Private Ocean LLC bought a new position in shares of TherapeuticsMD during the first quarter worth approximately $37,000. 78.93% of the stock is owned by institutional investors.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.
Featured Story: How to Invest in a Bull Market
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.